
21/06/2025
🧠💪 🥦👌
A clinical trial from Hunan in China has demonstrated benefits from sulforaphane in schizophrenia patients.
A 24-week double-blind randomised trial recruited schizophrenia patients with significant negative symptoms. Negative symptoms in schizophrenia refer to the absence or reduction of normal emotional and behavioural functions. They contrast with positive symptoms, which involve the presence of unusual behaviours like hallucinations and delusions. Participants were randomly assigned to receive either sulforaphane or placebo, and were required to complete at least one post-intervention assessment to evaluate changes in negative symptoms and cognitive functioning. Existing antipsychotic medication treatment regimens remained unchanged throughout the study.
Each sulforaphane tablet contained over 30 mg of glucoraphanin, capable of producing a minimum of 12 mg (approximately 68 μmol) of sulforaphane, and the dose was 2 per day.
A total of 42 patients were included in the statistical analysis, with 28 receiving sulforaphane and 14 assigned to placebo. Sulforaphane significantly reduced the Negative Symptom Score from the PANSS (Positive and Negative Syndrome Scale) 5-Factor model between groups (p = 0.007) and exhibited a significant time-by-group interaction (p = 0.023), with more pronounced group differences observed after 12 weeks compared to 24 weeks of treatment. Sulforaphane also demonstrated a significant reduction in the original PANSS Negative Symptom Score between groups (p = 0.029). However, it showed no significant effects on the MATRICS Consensus Cognitive Battery composite score or its sub-scores.
For more information see: https://pubmed.ncbi.nlm.nih.gov/40133020/